{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:01:45Z","timestamp":1793142105486,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"\n Importance<\/jats:title>\n Bipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To establish the safety and efficacy of psilocybin in patients with BDII in a current depressive episode.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a 12-week, open-label nonrandomized open-label trial conducted at Sheppard Pratt Hospital. Participants aged 18 to 65 years with BDII, a current depressive episode longer than 3 months, and documented insufficient benefit with at least 2 pharmacologic treatments during the current episode were invited to participate. Of 70 approached, 19 met inclusion criteria and were enrolled. The trial was conducted between April 14, 2021, and January 5, 2023.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n A single dose of synthetic psilocybin, 25 mg, was administered. Psychotropic medications were discontinued at least 2 weeks prior to dosing. Therapists met with patients for 3 sessions during pretreatment, during the 8-hour dosing day, and for 3 integration sessions posttreatment.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome measure was change in Montgomery-\u00c5sberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Secondary measures included MADRS scores 12 weeks posttreatment, the self-rated Quick Inventory of Depression Symptoms-Self Rating (QIDS-SR), and the self-rated Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF), each completed at baseline and all subsequent visits. Safety measures included the Columbia Suicide Severity Rating Scale (CSSRS) and the Young Mania Rating Scale (YMRS) completed at each visit.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 15 participants in this study (6 male and 9 female; mean [SD] age, 37.8 [11.6] years), all had lower scores at week 3, with a mean (SD) change of \u221224.00 (9.23) points on the MADRS, (Cohen\n d<\/jats:italic>\n \u2009=\u20094.08; 95% CI, \u221229.11 to \u221218.89;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Repeat measures analysis of variance showed lower MADRS scores at all tested posttreatment time points, including the end point (Cohen\n d<\/jats:italic>\n \u2009=\u20093.39; 95% CI, \u221233.19 to \u221216.95; adjusted\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). At week 3, 12 participants met the response criterion (50% decrease in MADRS), and 11 met remission criterion (MADRS score \u226410). At the study end point, 12 patients met both response and remission criteria. QIDS-SR scores and Q-LES-Q-SF scores demonstrated similar improvements. YMRS and CSSRS scores did not change significantly at posttreatment compared to baseline.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings in this open-label nonrandomized open-label trial suggest efficacy and safety of psilocybin with psychotherapy in BDII depression and supports further study of psychedelics in this population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2023.4685","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:02:07Z","timestamp":1701860527000},"page":"555","source":"Crossref","is-referenced-by-count":108,"title":["Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes"],"prefix":"10.1001","volume":"81","author":[{"given":"Scott T.","family":"Aaronson","sequence":"first","affiliation":[{"name":"Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore, Maryland"},{"name":"Department of Psychiatry, University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"van der Vaart","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Miller","sequence":"additional","affiliation":[{"name":"Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"LaPratt","sequence":"additional","affiliation":[{"name":"Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Swartz","sequence":"additional","affiliation":[{"name":"Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Shoultz","sequence":"additional","affiliation":[{"name":"Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo","family":"Lauterbach","sequence":"additional","affiliation":[{"name":"Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore, Maryland"},{"name":"Department of Psychiatry, University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold A.","family":"Sackeim","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University, New York"},{"name":"Department of Radiology, Columbia University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Suppes","sequence":"additional","affiliation":[{"name":"VA Palo Alto Health Care System, Palo Alto, California"},{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"yoi230093r1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/YCO.0b013e32834de3de","article-title":"The \u2018true\u2019 prevalence of bipolar II disorder.","volume":"25","author":"Merikangas","year":"2012","journal-title":"Curr Opin Psychiatry"},{"issue":"1-3","key":"yoi230093r2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jad.2010.05.014","article-title":"Functional impairment in bipolar II disorder: is it as disabling as bipolar I?","volume":"127","author":"Rosa","year":"2010","journal-title":"J Affect Disord"},{"issue":"1-3","key":"yoi230093r3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jad.2007.01.035","article-title":"Psychosocial impairment associated with bipolar II disorder.","volume":"104","author":"Ruggero","year":"2007","journal-title":"J Affect Disord"},{"issue":"4","key":"yoi230093r4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/bdi.v22.4","article-title":"Characteristics of bipolar I and II disorder: a study of 8766 individuals.","volume":"22","author":"Karanti","year":"2020","journal-title":"Bipolar Disord"},{"key":"yoi230093r5","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291722001489","article-title":"Characterizing the longitudinal course of symptoms and functioning in bipolar disorder.","author":"Mignogna","year":"2022","journal-title":"Psychol Med"},{"issue":"1","key":"yoi230093r6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40345-019-0175-7","article-title":"The existential crisis of bipolar II disorder.","volume":"8","author":"Gitlin","year":"2020","journal-title":"Int J Bipolar Disord"},{"key":"yoi230093r7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpsychires.2016.02.006","article-title":"Different characteristics associated with suicide attempts among bipolar I versus bipolar II disorder patients.","volume":"76","author":"Goffin","year":"2016","journal-title":"J Psychiatr Res"},{"issue":"11","key":"yoi230093r8","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1080\/03007995.2019.1636017","article-title":"Bipolar depression: the clinical characteristics and unmet needs of a complex disorder.","volume":"35","author":"McIntyre","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"yoi230093r9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/1471-244X-13-211","article-title":"Pharmacotherapy for bipolar disorder and concordance with treatment guidelines: survey of a general population sample referred to a tertiary care service.","volume":"13","author":"Paterniti","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"2","key":"yoi230093r10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.2018.20.issue-2","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"issue":"1","key":"yoi230093r11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/15622975.2017.1384850","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: acute and long-term treatment of mixed states in bipolar disorder.","volume":"19","author":"Grunze","year":"2018","journal-title":"World J Biol Psychiatry"},{"issue":"5","key":"yoi230093r12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.4088\/JCP.10m06523","article-title":"The pharmacologic treatment of bipolar disorder.","volume":"72","author":"Sachs","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi230093r13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19ac13181","article-title":"Wrestling with antidepressant use in bipolar disorder: the ongoing debate.","volume":"82","author":"Goldberg","year":"2021","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi230093r14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1192\/bjp.2018.257","article-title":"Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.","volume":"214","author":"Hidalgo-Mazzei","year":"2019","journal-title":"Br J Psychiatry"},{"issue":"3","key":"yoi230093r15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"issue":"4","key":"yoi230093r16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0269881120959614","article-title":"Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin.","volume":"35","author":"Jefsen","year":"2021","journal-title":"J Psychopharmacol"},{"key":"yoi230093r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2021.107467","article-title":"Improving cognitive functioning in major depressive disorder with psychedelics: a dimensional approach.","volume":"183","author":"Magaraggia","year":"2021","journal-title":"Neurobiol Learn Mem"},{"issue":"1","key":"yoi230093r18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00213-022-06297-0","article-title":"Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.","volume":"240","author":"Meccia","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"issue":"18","key":"yoi230093r19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"yoi230093r20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression.","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"yoi230093r21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/02698811211064720","article-title":"The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.","volume":"36","author":"Rucker","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"5","key":"yoi230093r23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/cns.2010.16.issue-5","article-title":"RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ).","volume":"16","author":"Chandler","year":"2010","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"yoi230093r24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the Hamilton Depression Rating Scale.","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J Affect Disord"},{"key":"yoi230093r25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"yoi230093r26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"5","key":"yoi230093r27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatry"},{"issue":"2","key":"yoi230093r28","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"issue":"12","key":"yoi230093r29","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi230093r30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"yoi230093r31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/02698811221131997","article-title":"Risks and benefits of psilocybin use in people with bipolar disorder: an international web-based survey on experiences of \u2018magic mushroom\u2019 consumption.","volume":"37","author":"Morton","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"12","key":"yoi230093r32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279073","article-title":"\u201cA sense of the bigger picture:\u201d a qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.","volume":"17","author":"DellaCrosse","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"yoi230093r33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41386-022-01424-z","article-title":"Does the trip matter? investigating the role of the subjective effects of psychedelics in persisting therapeutic effects.","volume":"48","author":"Nautiyal","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"yoi230093r34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jad.2016.07.011","article-title":"Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: systematic review and meta-analysis.","volume":"206","author":"Hunt","year":"2016","journal-title":"J Affect Disord"},{"key":"yoi230093r35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.660432","article-title":"Comorbid bipolar and alcohol use disorder-a therapeutic challenge.","volume":"12","author":"Grunze","year":"2021","journal-title":"Front Psychiatry"},{"key":"yoi230093r22","volume-title":"The Mini International Neuropsychiatric Interview (Version 7.0. 2) for DSM-5","author":"Sheehan","year":"2016"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2812443\/jamapsychiatry_aaronson_2023_oi_230093_1716936119.88887.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:27:01Z","timestamp":1717590421000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2812443"}},"subtitle":["A Nonrandomized Open-Label Trial"],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4685","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}